Novo Nordisk

News

Semaglutide heart benefits may go beyond weight loss

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

News

Novo Nordisk’s head of development Martin Holst Lange

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure

News

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for ra

News

Heart claims unlock Medicare coverage of obesity drugs

Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could b

Semaglutide heart benefits may go beyond weight loss

Wegovy sales double, as starting restrictions start to lift

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

Heart claims unlock Medicare coverage of obesity drugs

Takeda gets first OK for orexin narcolepsy drug, in China

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks